Exhibitors & Sponsors

ADC Therapeutics is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADC's) advancing proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

American Oncology Network (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success and viability of community oncology and other specialties. Founded in 2018, AON’s rapidly expanding network represents more than 300 providers practicing across 20 states. AON pioneers innovative healthcare solutions through its physician-led model, fostering value-based care that improves patient outcomes while reducing costs and expanding access to quality care. AON equips its network physicians with the tools they need to thrive independently while providing comprehensive support, integrated revenue-diversifying ancillary services, and practice management expertise, enabling physicians to focus on what matters most – providing the highest standard of care for every patient. AON is committed to promoting health equity by addressing disparities in cancer care and ensuring that all patients have access to the care they need to achieve optimal health outcomes. With a focus on innovation and collaboration, AON is shaping the future of community oncology. 

American Regent, Inc.®, a Daiichi Sankyo Group company, is an industry-leading injectable
manufacturer. For over 50 years, American Regent has been developing, manufacturing, and supplying quality generic and branded injectables for healthcare providers. For more than 20 years, we have been a leader in IV iron therapy.

American Regent is committed to US-based manufacturing. To that end, over the last several years we have made significant investments in expanding and modernizing our manufacturing facilities in Ohio and New York. This expansion will nearly double our capacity and allow us to better serve our customers now and in the future.

Speed counts. Flexibility matters. Reliability and quality are paramount. Because patients should never have to wait for the medications they need.

Welcome to Assertio

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.

Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., was recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies.  For more information, please visit Catalyst's website at www.catalystpharma.com.

Eisai Inc. is a human health care (hhc) company dedicated to pursuing innovative research and simplifying the treatment journey to help improve the lives of people affected by cancer, Alzheimer’s disease and other neurodegenerative conditions. Everything we do is guided by the simple principle that patients and their families come first, and we have a responsibility to listen to and learn from them.

Our hhc mission is the shared purpose that connects us to those we serve. It creates a network of powerful relationships that enable us to identify, understand and address unmet needs and healthcare disparities as we work towards achieving societal good.

Eisai Inc. is the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd. Our U.S. operations include discovery, research and development; manufacturing; global supply and logistics; and commercial activities.

To learn more, please visit https://us.eisai.com and connect with us on X and LinkedIn. For more information on our research, follow our dedicated neurology (LinkedIn and X) and oncology (LinkedIn and X) pages.

As a division of Fulgent Genetics, Fulgent Oncology provides personalized cancer diagnostics services through CSI Laboratories and Inform Diagnostics, Fulgent Genetics subsidiaries. Together, our labs have helped pathologists and oncologists accurately diagnose and treat their patients for over 25 years.

GTC offers genomic profiling of DNA, cfDNA, RNA and cfRNA for both solid and heme cancers globally. We have a turn-around time of 5-10 days and a QNS rate of less than 1% on tissue. Our cooperative model allows us to partner with laboratories, hospitals, oncology practices and medical professionals to share resources which create efficiencies in cost, turnaround time and quality. GTC’s testing is NY state approved and covered by Medicare and most insurances. Our RNA sequencing capabilities go beyond just the detection of fusions and incl alternative splicing, gene expression, and more.

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases-often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early-to late stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. 

 Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Switzerland, Sweden and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years. For more information, visit www.lantheus.com. 

With over 2,900 employees, Legend Biotech is the largest standalone cell therapy company and pioneer in treatments that change cancer care forever. The company is at the forefront of the CAR-T cell therapy revolution with CARVYKTI, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the US, Legend is building an end-to-end cell therapy by expanding its leadership to maximize CARVYKTI's patient access and therapeutic potential. From this platform, the company plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.

At Merck, our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer.  The potential to bring new hope to people with cancer drives our purpose and our commitment.  As part of our focus on cancer, Merck is committed to clinical research with one of the largest development programs in the industry across more than 30 tumor types.  

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram

At Pharmacyclics, an Abbvie company, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more at https://www.pharmacyclics.com/

Protocol Behavioral Health was founded to close a critical gap in mental health care for individuals undergoing cancer treatment. The company’s mission is to provide oncology-specific, evidence-based behavioral health services — ensuring that patients receive compassionate, clinically effective support tailored to the emotional and psychological challenges associated with cancer.
We envision a future where behavioral health is not an afterthought, but an integral, seamlessly embedded part of oncology care — improving patient outcomes, adherence to treatment, and overall quality of life.

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in our laboratories.  

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world. 

For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn. 

SAGA Diagnostics® is redefining the early detection of molecular residual disease (MRD), empowering treatment decisions with greater insight and confidence. Pathlight™, the company’s flagship product, is an ultra-sensitive, blood-based, multi-cancer MRD test that is now available for commercial use in the U.S. for patients with breast cancer.  

SAGA is partnering with pharmaceutical and biotechnology companies, as well as commercial entities, to support early through late-stage cancer development programs across a range of cancer types. 

Smirta Innovations builds technology that helps cancer centers do more with current staff. Our OncoSmart® platform applies AI, real-time context from your oncology EHR, and a holistic view of all services (infusion, labs, imaging, clinic) to recommend better scheduling and assignment decisions throughout the day. The result is a smoother “daily curve”: fewer midday peaks, more even workload distribution, and measurable improvements in patient access and staff experience.

With OncoSmart, organizations can:

• Optimize patient flow across services during scheduling.

• Automate treatment-room and nurse assignment with awareness of capacity, skill mix, and acuity.

• Maintain balanced patient-to-nurse ratios and spot bottlenecks early.

• Understand and track operations via historical and real-time dashboards and audit trails.

Practices report material impact—such as reductions in appointment delays and extended clinic hours, higher nurse utilization, faster assignment workflows, and increases in unlocked capacity—while keeping day-to-day tasks familiar for schedulers and nursing. OncoSmart overlays your existing EHR, captures physician schedules and no-shows, and supports leaders with the visibility needed to sustain change across locations. Learn more at smirta.com.

Learn more / request a demo: smirta.com

Sumitomo Pharma America and Pfizer Oncology are working together to redefine care for millions of patients living with cancer, and aspire to provide medicines that can improve lives and change treatment paradigms. By combining Sumitomo Pharma America’s commitment to purpose-driven science with Pfizer’s deep heritage and leadership in oncology, we are uniquely positioned to provide innovative treatments that fulfill significant unmet needs and make a meaningful difference in people’s lives.

Triage Cancer is a national, nonprofit organization that provides free education on the legal and practical issues that may impact individuals diagnosed with cancer and their caregivers through events, materials, and resources, including a Legal & Financial Navigation Program. In 2025, more than 1.4 million people were reached through our educational materials, websites, blogs, podcasts, and other programs.

ADC Therapeutics is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADC's) advancing proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

American Oncology Network (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success and viability of community oncology and other specialties. Founded in 2018, AON’s rapidly expanding network represents more than 300 providers practicing across 20 states. AON pioneers innovative healthcare solutions through its physician-led model, fostering value-based care that improves patient outcomes while reducing costs and expanding access to quality care. AON equips its network physicians with the tools they need to thrive independently while providing comprehensive support, integrated revenue-diversifying ancillary services, and practice management expertise, enabling physicians to focus on what matters most – providing the highest standard of care for every patient. AON is committed to promoting health equity by addressing disparities in cancer care and ensuring that all patients have access to the care they need to achieve optimal health outcomes. With a focus on innovation and collaboration, AON is shaping the future of community oncology. 

American Regent, Inc.®, a Daiichi Sankyo Group company, is an industry-leading injectable
manufacturer. For over 50 years, American Regent has been developing, manufacturing, and supplying quality generic and branded injectables for healthcare providers. For more than 20 years, we have been a leader in IV iron therapy.

American Regent is committed to US-based manufacturing. To that end, over the last several years we have made significant investments in expanding and modernizing our manufacturing facilities in Ohio and New York. This expansion will nearly double our capacity and allow us to better serve our customers now and in the future.

Speed counts. Flexibility matters. Reliability and quality are paramount. Because patients should never have to wait for the medications they need.

Welcome to Assertio

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.

Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., was recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies.  For more information, please visit Catalyst's website at www.catalystpharma.com.

Eisai Inc. is a human health care (hhc) company dedicated to pursuing innovative research and simplifying the treatment journey to help improve the lives of people affected by cancer, Alzheimer’s disease and other neurodegenerative conditions. Everything we do is guided by the simple principle that patients and their families come first, and we have a responsibility to listen to and learn from them.

Our hhc mission is the shared purpose that connects us to those we serve. It creates a network of powerful relationships that enable us to identify, understand and address unmet needs and healthcare disparities as we work towards achieving societal good.

Eisai Inc. is the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd. Our U.S. operations include discovery, research and development; manufacturing; global supply and logistics; and commercial activities.

To learn more, please visit https://us.eisai.com and connect with us on X and LinkedIn. For more information on our research, follow our dedicated neurology (LinkedIn and X) and oncology (LinkedIn and X) pages.

As a division of Fulgent Genetics, Fulgent Oncology provides personalized cancer diagnostics services through CSI Laboratories and Inform Diagnostics, Fulgent Genetics subsidiaries. Together, our labs have helped pathologists and oncologists accurately diagnose and treat their patients for over 25 years.

GTC offers genomic profiling of DNA, cfDNA, RNA and cfRNA for both solid and heme cancers globally. We have a turn-around time of 5-10 days and a QNS rate of less than 1% on tissue. Our cooperative model allows us to partner with laboratories, hospitals, oncology practices and medical professionals to share resources which create efficiencies in cost, turnaround time and quality. GTC’s testing is NY state approved and covered by Medicare and most insurances. Our RNA sequencing capabilities go beyond just the detection of fusions and incl alternative splicing, gene expression, and more.

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases-often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early-to late stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. 

 Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Switzerland, Sweden and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years. For more information, visit www.lantheus.com. 

With over 2,900 employees, Legend Biotech is the largest standalone cell therapy company and pioneer in treatments that change cancer care forever. The company is at the forefront of the CAR-T cell therapy revolution with CARVYKTI, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the US, Legend is building an end-to-end cell therapy by expanding its leadership to maximize CARVYKTI's patient access and therapeutic potential. From this platform, the company plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.

At Merck, our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer.  The potential to bring new hope to people with cancer drives our purpose and our commitment.  As part of our focus on cancer, Merck is committed to clinical research with one of the largest development programs in the industry across more than 30 tumor types.  

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram

At Pharmacyclics, an Abbvie company, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more at https://www.pharmacyclics.com/

Protocol Behavioral Health was founded to close a critical gap in mental health care for individuals undergoing cancer treatment. The company’s mission is to provide oncology-specific, evidence-based behavioral health services — ensuring that patients receive compassionate, clinically effective support tailored to the emotional and psychological challenges associated with cancer.
We envision a future where behavioral health is not an afterthought, but an integral, seamlessly embedded part of oncology care — improving patient outcomes, adherence to treatment, and overall quality of life.

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in our laboratories.  

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world. 

For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn. 

SAGA Diagnostics® is redefining the early detection of molecular residual disease (MRD), empowering treatment decisions with greater insight and confidence. Pathlight™, the company’s flagship product, is an ultra-sensitive, blood-based, multi-cancer MRD test that is now available for commercial use in the U.S. for patients with breast cancer.  

SAGA is partnering with pharmaceutical and biotechnology companies, as well as commercial entities, to support early through late-stage cancer development programs across a range of cancer types. 

Smirta Innovations builds technology that helps cancer centers do more with current staff. Our OncoSmart® platform applies AI, real-time context from your oncology EHR, and a holistic view of all services (infusion, labs, imaging, clinic) to recommend better scheduling and assignment decisions throughout the day. The result is a smoother “daily curve”: fewer midday peaks, more even workload distribution, and measurable improvements in patient access and staff experience.

With OncoSmart, organizations can:

• Optimize patient flow across services during scheduling.

• Automate treatment-room and nurse assignment with awareness of capacity, skill mix, and acuity.

• Maintain balanced patient-to-nurse ratios and spot bottlenecks early.

• Understand and track operations via historical and real-time dashboards and audit trails.

Practices report material impact—such as reductions in appointment delays and extended clinic hours, higher nurse utilization, faster assignment workflows, and increases in unlocked capacity—while keeping day-to-day tasks familiar for schedulers and nursing. OncoSmart overlays your existing EHR, captures physician schedules and no-shows, and supports leaders with the visibility needed to sustain change across locations. Learn more at smirta.com.

Learn more / request a demo: smirta.com

Sumitomo Pharma America and Pfizer Oncology are working together to redefine care for millions of patients living with cancer, and aspire to provide medicines that can improve lives and change treatment paradigms. By combining Sumitomo Pharma America’s commitment to purpose-driven science with Pfizer’s deep heritage and leadership in oncology, we are uniquely positioned to provide innovative treatments that fulfill significant unmet needs and make a meaningful difference in people’s lives.

Triage Cancer is a national, nonprofit organization that provides free education on the legal and practical issues that may impact individuals diagnosed with cancer and their caregivers through events, materials, and resources, including a Legal & Financial Navigation Program. In 2025, more than 1.4 million people were reached through our educational materials, websites, blogs, podcasts, and other programs.

ADC Therapeutics is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADC's) advancing proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

American Oncology Network (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success and viability of community oncology and other specialties. Founded in 2018, AON’s rapidly expanding network represents more than 300 providers practicing across 20 states. AON pioneers innovative healthcare solutions through its physician-led model, fostering value-based care that improves patient outcomes while reducing costs and expanding access to quality care. AON equips its network physicians with the tools they need to thrive independently while providing comprehensive support, integrated revenue-diversifying ancillary services, and practice management expertise, enabling physicians to focus on what matters most – providing the highest standard of care for every patient. AON is committed to promoting health equity by addressing disparities in cancer care and ensuring that all patients have access to the care they need to achieve optimal health outcomes. With a focus on innovation and collaboration, AON is shaping the future of community oncology. 

American Regent, Inc.®, a Daiichi Sankyo Group company, is an industry-leading injectable
manufacturer. For over 50 years, American Regent has been developing, manufacturing, and supplying quality generic and branded injectables for healthcare providers. For more than 20 years, we have been a leader in IV iron therapy.

American Regent is committed to US-based manufacturing. To that end, over the last several years we have made significant investments in expanding and modernizing our manufacturing facilities in Ohio and New York. This expansion will nearly double our capacity and allow us to better serve our customers now and in the future.

Speed counts. Flexibility matters. Reliability and quality are paramount. Because patients should never have to wait for the medications they need.

Welcome to Assertio

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.

Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., was recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies.  For more information, please visit Catalyst's website at www.catalystpharma.com.

Eisai Inc. is a human health care (hhc) company dedicated to pursuing innovative research and simplifying the treatment journey to help improve the lives of people affected by cancer, Alzheimer’s disease and other neurodegenerative conditions. Everything we do is guided by the simple principle that patients and their families come first, and we have a responsibility to listen to and learn from them.

Our hhc mission is the shared purpose that connects us to those we serve. It creates a network of powerful relationships that enable us to identify, understand and address unmet needs and healthcare disparities as we work towards achieving societal good.

Eisai Inc. is the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd. Our U.S. operations include discovery, research and development; manufacturing; global supply and logistics; and commercial activities.

To learn more, please visit https://us.eisai.com and connect with us on X and LinkedIn. For more information on our research, follow our dedicated neurology (LinkedIn and X) and oncology (LinkedIn and X) pages.

As a division of Fulgent Genetics, Fulgent Oncology provides personalized cancer diagnostics services through CSI Laboratories and Inform Diagnostics, Fulgent Genetics subsidiaries. Together, our labs have helped pathologists and oncologists accurately diagnose and treat their patients for over 25 years.

GTC offers genomic profiling of DNA, cfDNA, RNA and cfRNA for both solid and heme cancers globally. We have a turn-around time of 5-10 days and a QNS rate of less than 1% on tissue. Our cooperative model allows us to partner with laboratories, hospitals, oncology practices and medical professionals to share resources which create efficiencies in cost, turnaround time and quality. GTC’s testing is NY state approved and covered by Medicare and most insurances. Our RNA sequencing capabilities go beyond just the detection of fusions and incl alternative splicing, gene expression, and more.

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases-often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early-to late stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. 

 Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Switzerland, Sweden and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years. For more information, visit www.lantheus.com. 

With over 2,900 employees, Legend Biotech is the largest standalone cell therapy company and pioneer in treatments that change cancer care forever. The company is at the forefront of the CAR-T cell therapy revolution with CARVYKTI, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the US, Legend is building an end-to-end cell therapy by expanding its leadership to maximize CARVYKTI's patient access and therapeutic potential. From this platform, the company plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.

At Merck, our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer.  The potential to bring new hope to people with cancer drives our purpose and our commitment.  As part of our focus on cancer, Merck is committed to clinical research with one of the largest development programs in the industry across more than 30 tumor types.  

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram

At Pharmacyclics, an Abbvie company, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more at https://www.pharmacyclics.com/

Protocol Behavioral Health was founded to close a critical gap in mental health care for individuals undergoing cancer treatment. The company’s mission is to provide oncology-specific, evidence-based behavioral health services — ensuring that patients receive compassionate, clinically effective support tailored to the emotional and psychological challenges associated with cancer.
We envision a future where behavioral health is not an afterthought, but an integral, seamlessly embedded part of oncology care — improving patient outcomes, adherence to treatment, and overall quality of life.

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in our laboratories.  

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world. 

For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn. 

SAGA Diagnostics® is redefining the early detection of molecular residual disease (MRD), empowering treatment decisions with greater insight and confidence. Pathlight™, the company’s flagship product, is an ultra-sensitive, blood-based, multi-cancer MRD test that is now available for commercial use in the U.S. for patients with breast cancer.  

SAGA is partnering with pharmaceutical and biotechnology companies, as well as commercial entities, to support early through late-stage cancer development programs across a range of cancer types. 

Smirta Innovations builds technology that helps cancer centers do more with current staff. Our OncoSmart® platform applies AI, real-time context from your oncology EHR, and a holistic view of all services (infusion, labs, imaging, clinic) to recommend better scheduling and assignment decisions throughout the day. The result is a smoother “daily curve”: fewer midday peaks, more even workload distribution, and measurable improvements in patient access and staff experience.

With OncoSmart, organizations can:

• Optimize patient flow across services during scheduling.

• Automate treatment-room and nurse assignment with awareness of capacity, skill mix, and acuity.

• Maintain balanced patient-to-nurse ratios and spot bottlenecks early.

• Understand and track operations via historical and real-time dashboards and audit trails.

Practices report material impact—such as reductions in appointment delays and extended clinic hours, higher nurse utilization, faster assignment workflows, and increases in unlocked capacity—while keeping day-to-day tasks familiar for schedulers and nursing. OncoSmart overlays your existing EHR, captures physician schedules and no-shows, and supports leaders with the visibility needed to sustain change across locations. Learn more at smirta.com.

Learn more / request a demo: smirta.com

Sumitomo Pharma America and Pfizer Oncology are working together to redefine care for millions of patients living with cancer, and aspire to provide medicines that can improve lives and change treatment paradigms. By combining Sumitomo Pharma America’s commitment to purpose-driven science with Pfizer’s deep heritage and leadership in oncology, we are uniquely positioned to provide innovative treatments that fulfill significant unmet needs and make a meaningful difference in people’s lives.

Triage Cancer is a national, nonprofit organization that provides free education on the legal and practical issues that may impact individuals diagnosed with cancer and their caregivers through events, materials, and resources, including a Legal & Financial Navigation Program. In 2025, more than 1.4 million people were reached through our educational materials, websites, blogs, podcasts, and other programs.

ADC Therapeutics is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADC's) advancing proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

American Oncology Network (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success and viability of community oncology and other specialties. Founded in 2018, AON’s rapidly expanding network represents more than 300 providers practicing across 20 states. AON pioneers innovative healthcare solutions through its physician-led model, fostering value-based care that improves patient outcomes while reducing costs and expanding access to quality care. AON equips its network physicians with the tools they need to thrive independently while providing comprehensive support, integrated revenue-diversifying ancillary services, and practice management expertise, enabling physicians to focus on what matters most – providing the highest standard of care for every patient. AON is committed to promoting health equity by addressing disparities in cancer care and ensuring that all patients have access to the care they need to achieve optimal health outcomes. With a focus on innovation and collaboration, AON is shaping the future of community oncology. 

American Regent, Inc.®, a Daiichi Sankyo Group company, is an industry-leading injectable
manufacturer. For over 50 years, American Regent has been developing, manufacturing, and supplying quality generic and branded injectables for healthcare providers. For more than 20 years, we have been a leader in IV iron therapy.

American Regent is committed to US-based manufacturing. To that end, over the last several years we have made significant investments in expanding and modernizing our manufacturing facilities in Ohio and New York. This expansion will nearly double our capacity and allow us to better serve our customers now and in the future.

Speed counts. Flexibility matters. Reliability and quality are paramount. Because patients should never have to wait for the medications they need.

Welcome to Assertio

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.

Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., was recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies.  For more information, please visit Catalyst's website at www.catalystpharma.com.

Eisai Inc. is a human health care (hhc) company dedicated to pursuing innovative research and simplifying the treatment journey to help improve the lives of people affected by cancer, Alzheimer’s disease and other neurodegenerative conditions. Everything we do is guided by the simple principle that patients and their families come first, and we have a responsibility to listen to and learn from them.

Our hhc mission is the shared purpose that connects us to those we serve. It creates a network of powerful relationships that enable us to identify, understand and address unmet needs and healthcare disparities as we work towards achieving societal good.

Eisai Inc. is the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd. Our U.S. operations include discovery, research and development; manufacturing; global supply and logistics; and commercial activities.

To learn more, please visit https://us.eisai.com and connect with us on X and LinkedIn. For more information on our research, follow our dedicated neurology (LinkedIn and X) and oncology (LinkedIn and X) pages.

As a division of Fulgent Genetics, Fulgent Oncology provides personalized cancer diagnostics services through CSI Laboratories and Inform Diagnostics, Fulgent Genetics subsidiaries. Together, our labs have helped pathologists and oncologists accurately diagnose and treat their patients for over 25 years.

GTC offers genomic profiling of DNA, cfDNA, RNA and cfRNA for both solid and heme cancers globally. We have a turn-around time of 5-10 days and a QNS rate of less than 1% on tissue. Our cooperative model allows us to partner with laboratories, hospitals, oncology practices and medical professionals to share resources which create efficiencies in cost, turnaround time and quality. GTC’s testing is NY state approved and covered by Medicare and most insurances. Our RNA sequencing capabilities go beyond just the detection of fusions and incl alternative splicing, gene expression, and more.

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases-often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early-to late stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. 

 Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Switzerland, Sweden and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years. For more information, visit www.lantheus.com. 

With over 2,900 employees, Legend Biotech is the largest standalone cell therapy company and pioneer in treatments that change cancer care forever. The company is at the forefront of the CAR-T cell therapy revolution with CARVYKTI, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the US, Legend is building an end-to-end cell therapy by expanding its leadership to maximize CARVYKTI's patient access and therapeutic potential. From this platform, the company plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.

At Merck, our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer.  The potential to bring new hope to people with cancer drives our purpose and our commitment.  As part of our focus on cancer, Merck is committed to clinical research with one of the largest development programs in the industry across more than 30 tumor types.  

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram

At Pharmacyclics, an Abbvie company, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more at https://www.pharmacyclics.com/

Protocol Behavioral Health was founded to close a critical gap in mental health care for individuals undergoing cancer treatment. The company’s mission is to provide oncology-specific, evidence-based behavioral health services — ensuring that patients receive compassionate, clinically effective support tailored to the emotional and psychological challenges associated with cancer.
We envision a future where behavioral health is not an afterthought, but an integral, seamlessly embedded part of oncology care — improving patient outcomes, adherence to treatment, and overall quality of life.

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in our laboratories.  

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world. 

For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn. 

SAGA Diagnostics® is redefining the early detection of molecular residual disease (MRD), empowering treatment decisions with greater insight and confidence. Pathlight™, the company’s flagship product, is an ultra-sensitive, blood-based, multi-cancer MRD test that is now available for commercial use in the U.S. for patients with breast cancer.  

SAGA is partnering with pharmaceutical and biotechnology companies, as well as commercial entities, to support early through late-stage cancer development programs across a range of cancer types. 

Smirta Innovations builds technology that helps cancer centers do more with current staff. Our OncoSmart® platform applies AI, real-time context from your oncology EHR, and a holistic view of all services (infusion, labs, imaging, clinic) to recommend better scheduling and assignment decisions throughout the day. The result is a smoother “daily curve”: fewer midday peaks, more even workload distribution, and measurable improvements in patient access and staff experience.

With OncoSmart, organizations can:

• Optimize patient flow across services during scheduling.

• Automate treatment-room and nurse assignment with awareness of capacity, skill mix, and acuity.

• Maintain balanced patient-to-nurse ratios and spot bottlenecks early.

• Understand and track operations via historical and real-time dashboards and audit trails.

Practices report material impact—such as reductions in appointment delays and extended clinic hours, higher nurse utilization, faster assignment workflows, and increases in unlocked capacity—while keeping day-to-day tasks familiar for schedulers and nursing. OncoSmart overlays your existing EHR, captures physician schedules and no-shows, and supports leaders with the visibility needed to sustain change across locations. Learn more at smirta.com.

Learn more / request a demo: smirta.com

Sumitomo Pharma America and Pfizer Oncology are working together to redefine care for millions of patients living with cancer, and aspire to provide medicines that can improve lives and change treatment paradigms. By combining Sumitomo Pharma America’s commitment to purpose-driven science with Pfizer’s deep heritage and leadership in oncology, we are uniquely positioned to provide innovative treatments that fulfill significant unmet needs and make a meaningful difference in people’s lives.

Triage Cancer is a national, nonprofit organization that provides free education on the legal and practical issues that may impact individuals diagnosed with cancer and their caregivers through events, materials, and resources, including a Legal & Financial Navigation Program. In 2025, more than 1.4 million people were reached through our educational materials, websites, blogs, podcasts, and other programs.

ADC Therapeutics is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADC's) advancing proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

American Oncology Network (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success and viability of community oncology and other specialties. Founded in 2018, AON’s rapidly expanding network represents more than 300 providers practicing across 20 states. AON pioneers innovative healthcare solutions through its physician-led model, fostering value-based care that improves patient outcomes while reducing costs and expanding access to quality care. AON equips its network physicians with the tools they need to thrive independently while providing comprehensive support, integrated revenue-diversifying ancillary services, and practice management expertise, enabling physicians to focus on what matters most – providing the highest standard of care for every patient. AON is committed to promoting health equity by addressing disparities in cancer care and ensuring that all patients have access to the care they need to achieve optimal health outcomes. With a focus on innovation and collaboration, AON is shaping the future of community oncology. 

American Regent, Inc.®, a Daiichi Sankyo Group company, is an industry-leading injectable
manufacturer. For over 50 years, American Regent has been developing, manufacturing, and supplying quality generic and branded injectables for healthcare providers. For more than 20 years, we have been a leader in IV iron therapy.

American Regent is committed to US-based manufacturing. To that end, over the last several years we have made significant investments in expanding and modernizing our manufacturing facilities in Ohio and New York. This expansion will nearly double our capacity and allow us to better serve our customers now and in the future.

Speed counts. Flexibility matters. Reliability and quality are paramount. Because patients should never have to wait for the medications they need.

Welcome to Assertio

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.

Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., was recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies.  For more information, please visit Catalyst's website at www.catalystpharma.com.

Eisai Inc. is a human health care (hhc) company dedicated to pursuing innovative research and simplifying the treatment journey to help improve the lives of people affected by cancer, Alzheimer’s disease and other neurodegenerative conditions. Everything we do is guided by the simple principle that patients and their families come first, and we have a responsibility to listen to and learn from them.

Our hhc mission is the shared purpose that connects us to those we serve. It creates a network of powerful relationships that enable us to identify, understand and address unmet needs and healthcare disparities as we work towards achieving societal good.

Eisai Inc. is the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd. Our U.S. operations include discovery, research and development; manufacturing; global supply and logistics; and commercial activities.

To learn more, please visit https://us.eisai.com and connect with us on X and LinkedIn. For more information on our research, follow our dedicated neurology (LinkedIn and X) and oncology (LinkedIn and X) pages.

As a division of Fulgent Genetics, Fulgent Oncology provides personalized cancer diagnostics services through CSI Laboratories and Inform Diagnostics, Fulgent Genetics subsidiaries. Together, our labs have helped pathologists and oncologists accurately diagnose and treat their patients for over 25 years.

GTC offers genomic profiling of DNA, cfDNA, RNA and cfRNA for both solid and heme cancers globally. We have a turn-around time of 5-10 days and a QNS rate of less than 1% on tissue. Our cooperative model allows us to partner with laboratories, hospitals, oncology practices and medical professionals to share resources which create efficiencies in cost, turnaround time and quality. GTC’s testing is NY state approved and covered by Medicare and most insurances. Our RNA sequencing capabilities go beyond just the detection of fusions and incl alternative splicing, gene expression, and more.

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases-often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early-to late stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. 

 Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Switzerland, Sweden and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years. For more information, visit www.lantheus.com. 

With over 2,900 employees, Legend Biotech is the largest standalone cell therapy company and pioneer in treatments that change cancer care forever. The company is at the forefront of the CAR-T cell therapy revolution with CARVYKTI, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the US, Legend is building an end-to-end cell therapy by expanding its leadership to maximize CARVYKTI's patient access and therapeutic potential. From this platform, the company plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.

At Merck, our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer.  The potential to bring new hope to people with cancer drives our purpose and our commitment.  As part of our focus on cancer, Merck is committed to clinical research with one of the largest development programs in the industry across more than 30 tumor types.  

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram

At Pharmacyclics, an Abbvie company, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more at https://www.pharmacyclics.com/

Protocol Behavioral Health was founded to close a critical gap in mental health care for individuals undergoing cancer treatment. The company’s mission is to provide oncology-specific, evidence-based behavioral health services — ensuring that patients receive compassionate, clinically effective support tailored to the emotional and psychological challenges associated with cancer.
We envision a future where behavioral health is not an afterthought, but an integral, seamlessly embedded part of oncology care — improving patient outcomes, adherence to treatment, and overall quality of life.

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in our laboratories.  

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world. 

For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn. 

SAGA Diagnostics® is redefining the early detection of molecular residual disease (MRD), empowering treatment decisions with greater insight and confidence. Pathlight™, the company’s flagship product, is an ultra-sensitive, blood-based, multi-cancer MRD test that is now available for commercial use in the U.S. for patients with breast cancer.  

SAGA is partnering with pharmaceutical and biotechnology companies, as well as commercial entities, to support early through late-stage cancer development programs across a range of cancer types. 

Smirta Innovations builds technology that helps cancer centers do more with current staff. Our OncoSmart® platform applies AI, real-time context from your oncology EHR, and a holistic view of all services (infusion, labs, imaging, clinic) to recommend better scheduling and assignment decisions throughout the day. The result is a smoother “daily curve”: fewer midday peaks, more even workload distribution, and measurable improvements in patient access and staff experience.

With OncoSmart, organizations can:

• Optimize patient flow across services during scheduling.

• Automate treatment-room and nurse assignment with awareness of capacity, skill mix, and acuity.

• Maintain balanced patient-to-nurse ratios and spot bottlenecks early.

• Understand and track operations via historical and real-time dashboards and audit trails.

Practices report material impact—such as reductions in appointment delays and extended clinic hours, higher nurse utilization, faster assignment workflows, and increases in unlocked capacity—while keeping day-to-day tasks familiar for schedulers and nursing. OncoSmart overlays your existing EHR, captures physician schedules and no-shows, and supports leaders with the visibility needed to sustain change across locations. Learn more at smirta.com.

Learn more / request a demo: smirta.com

Sumitomo Pharma America and Pfizer Oncology are working together to redefine care for millions of patients living with cancer, and aspire to provide medicines that can improve lives and change treatment paradigms. By combining Sumitomo Pharma America’s commitment to purpose-driven science with Pfizer’s deep heritage and leadership in oncology, we are uniquely positioned to provide innovative treatments that fulfill significant unmet needs and make a meaningful difference in people’s lives.

Triage Cancer is a national, nonprofit organization that provides free education on the legal and practical issues that may impact individuals diagnosed with cancer and their caregivers through events, materials, and resources, including a Legal & Financial Navigation Program. In 2025, more than 1.4 million people were reached through our educational materials, websites, blogs, podcasts, and other programs.

ADC Therapeutics is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADC's) advancing proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

American Oncology Network (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success and viability of community oncology and other specialties. Founded in 2018, AON’s rapidly expanding network represents more than 300 providers practicing across 20 states. AON pioneers innovative healthcare solutions through its physician-led model, fostering value-based care that improves patient outcomes while reducing costs and expanding access to quality care. AON equips its network physicians with the tools they need to thrive independently while providing comprehensive support, integrated revenue-diversifying ancillary services, and practice management expertise, enabling physicians to focus on what matters most – providing the highest standard of care for every patient. AON is committed to promoting health equity by addressing disparities in cancer care and ensuring that all patients have access to the care they need to achieve optimal health outcomes. With a focus on innovation and collaboration, AON is shaping the future of community oncology. 

American Regent, Inc.®, a Daiichi Sankyo Group company, is an industry-leading injectable
manufacturer. For over 50 years, American Regent has been developing, manufacturing, and supplying quality generic and branded injectables for healthcare providers. For more than 20 years, we have been a leader in IV iron therapy.

American Regent is committed to US-based manufacturing. To that end, over the last several years we have made significant investments in expanding and modernizing our manufacturing facilities in Ohio and New York. This expansion will nearly double our capacity and allow us to better serve our customers now and in the future.

Speed counts. Flexibility matters. Reliability and quality are paramount. Because patients should never have to wait for the medications they need.

Welcome to Assertio

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.

Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., was recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies.  For more information, please visit Catalyst's website at www.catalystpharma.com.

Eisai Inc. is a human health care (hhc) company dedicated to pursuing innovative research and simplifying the treatment journey to help improve the lives of people affected by cancer, Alzheimer’s disease and other neurodegenerative conditions. Everything we do is guided by the simple principle that patients and their families come first, and we have a responsibility to listen to and learn from them.

Our hhc mission is the shared purpose that connects us to those we serve. It creates a network of powerful relationships that enable us to identify, understand and address unmet needs and healthcare disparities as we work towards achieving societal good.

Eisai Inc. is the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd. Our U.S. operations include discovery, research and development; manufacturing; global supply and logistics; and commercial activities.

To learn more, please visit https://us.eisai.com and connect with us on X and LinkedIn. For more information on our research, follow our dedicated neurology (LinkedIn and X) and oncology (LinkedIn and X) pages.

As a division of Fulgent Genetics, Fulgent Oncology provides personalized cancer diagnostics services through CSI Laboratories and Inform Diagnostics, Fulgent Genetics subsidiaries. Together, our labs have helped pathologists and oncologists accurately diagnose and treat their patients for over 25 years.

GTC offers genomic profiling of DNA, cfDNA, RNA and cfRNA for both solid and heme cancers globally. We have a turn-around time of 5-10 days and a QNS rate of less than 1% on tissue. Our cooperative model allows us to partner with laboratories, hospitals, oncology practices and medical professionals to share resources which create efficiencies in cost, turnaround time and quality. GTC’s testing is NY state approved and covered by Medicare and most insurances. Our RNA sequencing capabilities go beyond just the detection of fusions and incl alternative splicing, gene expression, and more.

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases-often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early-to late stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. 

 Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Switzerland, Sweden and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years. For more information, visit www.lantheus.com. 

With over 2,900 employees, Legend Biotech is the largest standalone cell therapy company and pioneer in treatments that change cancer care forever. The company is at the forefront of the CAR-T cell therapy revolution with CARVYKTI, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the US, Legend is building an end-to-end cell therapy by expanding its leadership to maximize CARVYKTI's patient access and therapeutic potential. From this platform, the company plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.

At Merck, our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer.  The potential to bring new hope to people with cancer drives our purpose and our commitment.  As part of our focus on cancer, Merck is committed to clinical research with one of the largest development programs in the industry across more than 30 tumor types.  

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram

At Pharmacyclics, an Abbvie company, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more at https://www.pharmacyclics.com/

Protocol Behavioral Health was founded to close a critical gap in mental health care for individuals undergoing cancer treatment. The company’s mission is to provide oncology-specific, evidence-based behavioral health services — ensuring that patients receive compassionate, clinically effective support tailored to the emotional and psychological challenges associated with cancer.
We envision a future where behavioral health is not an afterthought, but an integral, seamlessly embedded part of oncology care — improving patient outcomes, adherence to treatment, and overall quality of life.

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in our laboratories.  

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world. 

For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn. 

SAGA Diagnostics® is redefining the early detection of molecular residual disease (MRD), empowering treatment decisions with greater insight and confidence. Pathlight™, the company’s flagship product, is an ultra-sensitive, blood-based, multi-cancer MRD test that is now available for commercial use in the U.S. for patients with breast cancer.  

SAGA is partnering with pharmaceutical and biotechnology companies, as well as commercial entities, to support early through late-stage cancer development programs across a range of cancer types. 

Smirta Innovations builds technology that helps cancer centers do more with current staff. Our OncoSmart® platform applies AI, real-time context from your oncology EHR, and a holistic view of all services (infusion, labs, imaging, clinic) to recommend better scheduling and assignment decisions throughout the day. The result is a smoother “daily curve”: fewer midday peaks, more even workload distribution, and measurable improvements in patient access and staff experience.

With OncoSmart, organizations can:

• Optimize patient flow across services during scheduling.

• Automate treatment-room and nurse assignment with awareness of capacity, skill mix, and acuity.

• Maintain balanced patient-to-nurse ratios and spot bottlenecks early.

• Understand and track operations via historical and real-time dashboards and audit trails.

Practices report material impact—such as reductions in appointment delays and extended clinic hours, higher nurse utilization, faster assignment workflows, and increases in unlocked capacity—while keeping day-to-day tasks familiar for schedulers and nursing. OncoSmart overlays your existing EHR, captures physician schedules and no-shows, and supports leaders with the visibility needed to sustain change across locations. Learn more at smirta.com.

Learn more / request a demo: smirta.com

Sumitomo Pharma America and Pfizer Oncology are working together to redefine care for millions of patients living with cancer, and aspire to provide medicines that can improve lives and change treatment paradigms. By combining Sumitomo Pharma America’s commitment to purpose-driven science with Pfizer’s deep heritage and leadership in oncology, we are uniquely positioned to provide innovative treatments that fulfill significant unmet needs and make a meaningful difference in people’s lives.

Triage Cancer is a national, nonprofit organization that provides free education on the legal and practical issues that may impact individuals diagnosed with cancer and their caregivers through events, materials, and resources, including a Legal & Financial Navigation Program. In 2025, more than 1.4 million people were reached through our educational materials, websites, blogs, podcasts, and other programs.